Thromb Haemost 2009; 101(05): 813-817
DOI: 10.1160/TH08-11-0747
Rapid and Short Communication
Schattauer GmbH

Do common prothrombotic mutations influence the risk of cerebral ischaemia in patients with patent foramen ovale?

Systematic review and meta-analysis

Authors

  • Alessandro Pezzini

    1   Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia
  • Mario Grassi

    2   Dipartimento di Scienze Sanitarie Applicate, Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia
  • Elisabetta Del Zotto

    1   Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia
    3   Dipartimento di Scienze Biomediche e Biotecnologie, Università degli Studi di Brescia, Brescia, Italia
  • Alessia Giossi

    1   Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia
  • Irene Volonghi

    1   Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia
  • Paolo Costa

    1   Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia
  • Armin Grau

    4   Department of Neurology, Städtisches Klinikum, Ludwigshafen, Germany
  • Mauro Magoni

    5   Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia
  • Alessandro Padovani

    1   Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia
  • Christoph Lichy

    6   Department of Neurology, University of Heidelberg, Heidelberg, Germany
Weitere Informationen

Publikationsverlauf

Received: 14. November 2008

Accepted after minor revision: 11. Januar 2009

Publikationsdatum:
24. November 2017 (online)

Preview

Summary

Conflicting results are available on the association of prothrombotic genetic abnormalities with patent foramen ovale (PFO)-related cerebral ischaemia. We comprehensively sought and identified studies of the association of both the factor V Leiden (FVG1691A mutation) and the prothrombin mutation (PTG20210A mutation) with PFO-related cerebral ischaemia and did meta-analyses to assess the evidence for such a relation. We analysed data from six eligible studies in 856 cases and 1,001 control subjects. Additional unpublished data from a new series including 463 subjects were also entered into the analysis. The PTG20210A variant was significantly associated with PFO-related stroke in comparison with both control subjects (odds ratio [OR] 3.85; 95% confidence interval [CI] 2.22 to 6.66) and non-PFO-associ ated stroke patients (OR 2.31; 95% CI 1.20 to 4.43), whereas a trend toward an association was observed for the FVG1691A mutation (OR 1.18; 95% CI 0.73 to 1.90, compared to control subjects; OR 1.14; 95% CI 0.62 to 2.09, compared to non-PFO-associated stroke patients). The status of carrier of either the FVG1691A mutation or the PTG20210A variant was associated with a risk for stroke of 1.98 (95% CI 1.38 to 2.83) and 1.62 (95% CI 1.03 to 2.57), as compared to control subjects and non-PFO-associated stroke patients, respectively. Addition of common prothrombotic genetic variants to standard initial screening may contribute to stratifying PFO-associated stroke patients at different risk of ischaemic events and targeting secondary prevention strategies.